Loading
Shared decision-making support tool / Cognitive Abnormality · Interventional Study
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered interventional study designed to evaluate a shared decision-making support tool for blood biomarker testing in primary care using simulated clinical encounters. No results have been posted; the trial has not yet begun recruitment. The study will measure provider and patient perceptions of shared decision-making via validated scales (OPTION-5 and SDM-Q-9) as single time-point outcomes in a simulated environment.
Interventional, Single Group, Open label, Health Services Research purpose. Cognitive Abnormality; age from 50 Years; accepts healthy volunteers. Intervention: Simulation clinical encounters. Compared with: Standard clinical encounter without the decision-support tool.. n = 70. 1 site: United States.
This is a registered interventional study designed to evaluate a shared decision-making support tool for blood biomarker testing in primary care using simulated clinical encounters. No results have been posted; the trial has not yet begun recruitment. The study will measure provider and patient perceptions of shared decision-making via validated scales (OPTION-5 and SDM-Q-9) as single time-point outcomes in a simulated environment.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study addresses implementation of shared decision-making tools for cognitive assessment in primary care. Once results are available, findings will inform whether decision-support tools improve the process (but not necessarily the outcomes) of biomarker testing discussions.
This is a study registration with no reported results; the trial is not yet recruiting and measures shared decision-making process outcomes (OPTION-5, SDM-Q-9) in a simulated clinical setting, representing early-phase implementation research.
As stated by the source record.
Quoted from the source exactly as published.
This study addresses implementation of shared decision-making tools for cognitive assessment in primary care. Once results are available, findings will inform whether decision-support tools improve the process (but not necessarily the outcomes) of biomarker testing discussions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07812337). This is a study registration, not published results. Lead sponsor: University of Wisconsin, Madison. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 70 participants (ESTIMATED). Conditions: Cognitive Abnormality. Interventions: OTHER: Shared decision-making support tool. Primary outcome measures: Effectiveness of the tool on shared decision-making as measured by OPTION-5 Score , This is a single time point outcome measure. In Simulation 2, providers participants will complete OPTION-5 immediately after they participate in the high fidelity clinical encounter session.; Effectiveness of the tool on shared decision-making assessed by SDM-Q-9. , This is a single time point outcome measure. In Simulation 2, patients participants will complete SDM-Q-9 immediately after they participate in the high fidelity clinical encounter session.. Brief summary: The goal of the current study is to evaluate a decision-support tool intended to help primary care providers (PCPs) communicate with patients about blood biomarker testing for Alzheimer's Disease, enhancing shared-decision making and information sharing in the clinical space. The main questions it aims to answer are: * Is the decision-support tool accepted and easy to use for PCPs? * Does using the tool improve shared decision-making during clinical encounters? Researchers will compare clinical encounters between PCPs who do not use the tool to discuss blood biomarker testing for Alzheimer's Disease, versus PCPs who have been trained to utilize the tool during clinical encounters to see whether the tool effectively facilitates shared-decision making.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.